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Abstract 
Background: SIVmac239 is a commonly used virus in non-human primate models of HIV transmission and patho-
genesis. Previous studies identified four suboptimal nucleotides in the SIVmac239 genome, which putatively inhibit its 
replicative capacity. Since all four suboptimal changes revert to the optimal nucleotide consensus sequence during 
viral replication in vitro and in vivo, we sought to eliminate the variability of generating these mutations de novo and 
increase the overall consistency of viral replication by introducing the optimal nucleotides directly to the infectious 
molecular clone.
Results: Using site directed mutagenesis of the full-length/nef-open SIVmac239 clone, we reverted all four nucleo-
tides to the consensus/optimal base to generate SIVmac239Opt and subsequently tested its infectivity and replicative 
capacity in vitro and in vivo. In primary and cell line cultures, we observed that the optimized virus displayed con-
sistent modest but not statistically significant increases in replicative kinetics compared to wild type. In vivo, SIVma-
c239Opt replicated to high peak titers with an average of 1.2 × 108 viral RNA copies/ml at day 12 following intrarectal 
challenge, reaching set-point viremia of 1.2 × 106 viral RNA copies/ml by day 28. Although the peak and set point 
viremia means were not statistically different from the original “wild type” SIVmac239, viral load variation at set point 
was greater for SIVmac239WT compared to SIVmac239Opt (p = 0.0015) demonstrating a greater consistency of the 
optimized virus. Synonymous mutations were added to the integrase gene of SIVmac239Opt to generate a molecular 
tag consisting of ten genetically distinguishable viral variants referred to as SIVmac239OptX (Del Prete et al., J Virol. 
doi:10.1128/JVI.01026-14, 2014). Replication dynamics in vitro of these optimized clones were not statistically different 
from the parental clones. Interestingly, the consistently observed rapid reversion of the primer binding site subopti-
mal nucleotide is not due to viral RT error but is changed post-integration of a mismatched base via host proofread-
ing mechanisms.
Conclusions: Overall, our results demonstrate that SIVmac239Opt is a functional alternative to parental SIVmac239 
with marginally faster replication dynamics and with increased replication uniformity providing a more consistent and 
reproducible infection model in nonhuman primates.
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Background
Modeling HIV disease using non-human primate (NHP) 
models is an essential tool to gain a better understanding 
of viral transmission, pathogenesis, and to evaluate treat-
ment and prevention approaches, etc. One of the most 
commonly used viruses for this purpose is SIVmac239—a 
viral clone that yields high viral loads and causes progres-
sion to AIDS in rhesus macaques. One potential weak-
ness in using SIVmac239 is that the standard infectious 
molecular clone of SIVmac239 bears four suboptimal 
nucleotides in its genome [1] that may increase experi-
mental variability as the virus must first generate the cor-
rected mutations and then these corrected viruses must 
be selected over time. These four, suboptimal nucleotides 
in SIVmac239 were identified over a decade ago [1] and 
are presumed to be lab-generated errors originating dur-
ing the cloning process or minor variants found at the 
terminal stages of disease in the animal from which SIV-
mac239 was derived. These four suboptimal mutations 
are found in the primer binding site, Pol (RT and Int), 
and Env (overlapping with second exon of Tat and Rev) 
[1]. Importantly, the primer binding site mutation results 
in a mismatch to tRNA3Lys, potentially reducing efficient 
binding of the tRNA primer and thereby limiting or 
delaying reverse transcription [2]. It has also been postu-
lated that tRNA5Lys could be used as primer for lentiviral 
RT initiation [3], but with reduced replicative capacity. 
Furthermore, it is unclear if there is sufficient expres-
sion of tRNA5Lys in host cells [4] and additional evidence 
indicates that tRNA5Lys was not detected in viral genomes 
[5]. The suboptimal nucleotide in Env represents a syn-
onymous mutation in gp41, but causes non-synonymous 
mutations in both Tat and Rev. The two Pol mutations lie 
in RT and Int and are presumed to interfere with proper 
protein folding, although the exact mechanism by which 
these nucleotides adversely effect viral replication is not 
known.
Although the suboptimal mutations can be found in a 
small fraction of divergent SIV lineages [3] and may rep-
resent natural polymorphisms, it is clear that each of the 
four variants reverts to the SIV optimal nucleotide con-
taining consensus sequence upon replication in vitro and 
in vivo [1, 6]. Because this virus is consistently patho-
genic in vivo, no effort was made to correct these four 
bases within the clone itself. Indeed, an additional muta-
tion within the original clone that prematurely truncated 
nef was corrected [7] to restore nef function, but these 
additional four suboptimal (but functional) nucleotides 
remained.
The time required for these mutations to be corrected 
by random RT error varies from one animal to the next. 
We posit that the differences in the time it takes to gen-
erate these corrections in vivo and their relative fitness 
advantages can alter viral replication kinetics during pri-
mary infection, increasing the overall variability of viral 
replication between animals. These potential differences 
during primary infection can alter the dynamic balance 
between host and virus, thereby adding an extra, uncon-
trolled variable into each experiment. In high-dose chal-
lenge models, using the suboptimal virus is less likely 
to be problematic since the probability of generating 
these mutations at nearly the same time between ani-
mals increases with a higher effective dose. Since the 
viral reverse transcriptase makes 1–2 random errors per 
genome per RT cycle [8, 9], a high-dose challenge, in 
which many infectious events occur simultaneously, may 
provide each of the four mutations an opportunity to be 
corrected within the first few days, thereby limiting the 
variability between animals. Selection of each variant will 
then be determined by the relative fitness advantage/cost 
of each optimal/suboptimal nucleotide. The differences in 
replication kinetics caused by these suboptimal changes 
may be unimportant or too subtle to be detected in a 
high-dose model. However, since the demonstration that 
limited numbers of Transmitted/Founder (T/F) viruses 
initiate most HIV-1 infections [10–16], NHP research 
frequently utilizes a repeated or single limited-dose chal-
lenge model for mucosal infections [17–20] in an effort to 
more accurately model mucosal HIV-1 infection. In this 
approach, much lower quantities of SIV are used to chal-
lenge animals, which drastically reduces the probability 
that the suboptimal SIVmac239 nucleotides will all be 
corrected within the first few rounds of reverse transcrip-
tion. In fact, given the random accumulation of muta-
tions during acute infection with a single variant, it may 
require weeks before any of the suboptimal mutations are 
corrected by reverse transcription error. We hypothesize 
that the variation in the kinetics of reversion of subop-
timal nucleotides in limited-dose challenge models using 
SIVmac239 influences viral replicative capacity and may 
inadvertently increase variability between animals. For 
studies where the timing of systemic dissemination or 
determining which virus/host interactions are critical to 
block infection, we postulate that the stochastic nature 
of when these mutations occur can drastically affect 
the time to systemic dissemination or the reproducibil-
ity of vaccine efficacy. Furthermore, this variability may 
be exacerbated by using in vitro infection-derived chal-
lenge stocks in which some viruses in the stock may 
already be corrected at the time of infection, while oth-
ers remain suboptimal. Using this model, animals could 
be infected with either an optimal or suboptimal virus or 
by some combination thereof, effectively increasing the 
overall variability between animals. Here we report the 
generation and characterization of a SIVmac239 clone, 
designated SIVmac239Opt, with all four documented 
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suboptimal nucleotides corrected. This virus showed a 
modest increase in replication over the original “wild 
type” SIVmac239 clone in vitro and in vivo, but overall 
was not significantly different than parental virus. How-
ever SIVmac239Opt was significantly less variable at set-
point viremia following intrarectal infection than wild 
type SIVmac239. Use of this virus may be advantageous 
for various NHP studies that require greater consistency 
between animals using a limited challenge dose.
Results
Generating SIVmac239Opt
It has been reported that the reference clone of “wild 
type” SIVmac239 bears four suboptimal mutations in its 
genome in the 5′LTR (PBS), Pol (RT, and IN), and Env 
(gp41, Tat, and Rev) (Figure 1) [1, 6]. These nucleotides 
are rarely found in published viral sequences and revert 
to an SIV consensus sequence following in vitro or in 
vivo passage, and it has been suggested that they were 
artificially introduced in the process of deriving the SIV-
mac239 molecular clone. Here we generated a molecular 
clone of SIVmac239 with these sites corrected. The gen-
eration of this clone was accomplished using site directed 
mutagenesis with primers containing the “optimal” 
nucleotide designed to amplify the regions of the genome 
containing suboptimal nucleotides, and subsequently 
using Seamless technology to reassemble the fragments 
into one infectious molecular clone. Once the genome 
was reassembled, the entire viral genome was sequenced 
to ensure that the four suboptimal nucleotides had 
been changed and that no other errors had been intro-
duced. The full genome was identical to wild type SIV-
mac239 (SIVmac239WT), except for the four anticipated 
nucleotides we modified (Figure  1). The final corrected 
clone was termed SIVmac239Opt.
Protein characterization
Following mutagenesis, virus was produced by trans-
fection for standard biochemical analyses of SIVma-
c239Opt compared to SIVmac239WT. Cell-free virus 
pellets were run on an SDS-PAGE gel, which was sub-
sequently stained with Coomassie blue to compare 
protein expression patterns between the wild type and 
optimized viruses (Figure 2a). Banding patterns between 
wild type and optimized samples mapped identically, 
indicating that both the relative quantity and folding of 
the observed viral proteins was the same in each sample. 
Western blots were then performed by probing for Env 
(gp41, and gp120), and the p27 (CU) protein using spe-
cific monoclonal antibodies (Figure 2b). In all cases, pro-
teins extracted from both wild type and optimized virus 
protein expression levels were indistinguishable.
In vitro characterization
To further characterize the SIVmac239Opt clone, we 
performed infectivity and replication assays compar-
ing SIVmac239Opt and SIVmac239WT. The TZM-
bl reporter assay was used to measure infectivity of 
transfection-produced stocks. Infectivity was identical 
between the viruses both containing 1.3  ×  105  IU/ml. 
In vitro replicative capacity was determined by infecting 
enriched CD4+ T cells from three independent, Indian-
origin rhesus macaque PBMCs. Samples were collected 
every 3–4 days for 14 days, and virus measured using a 
SIV p27 antigen ELISA. Results from all three PBMC cul-
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Figure 1 Identification of point mutations in SIVmac239WT. Schematic depiction of the SIVmac239 genome with the four mutated sites indicated. 
The suboptimal nucleotides are found within the 5′ LTR at the primer binding site (PBS) (1), in Pol (RT, INT) (2, 3), and Env (Rev 2nd exon, Tat 2nd 
exon, and gp41) (4).
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replicated at similar rates, however both peak and final 
set point viremia were modestly higher in samples 
infected with the optimized virus compared to the wild 
type. The peak values ranged from 8 × 104 to 3 × 105 in 
SIVmac239Opt compared with 2  ×  104 to 2  ×  105 for 
SIVmac239WT (Figure 3). In one PBMC culture (MacA) 
the SIVmac239Opt produced significantly higher p27 
than wild type (p  =  0.005), but this difference was not 
seen in the other replicates and combining all data, we 
found no statistical differences between viruses in vitro 
(p = 0.232 ANOVA).
In vivo characterization
Four purpose-bred, Indian-origin rhesus macaques were 
challenged intrarectally with SIVmac239Opt produced 
by transfection of 239T cells. The viral loads obtained 
by frequent blood draws were compared with those of 
rhesus macaques which had previously been infected 
intrarectally with SIVmac239 [21]. SIVmac239Opt 
reached peak viremia by day 12 with vRNA measure-
ments ranging from 3.3  ×  107 to 2.8  ×  108 viral RNA 
copies/ml (Figure  4). Historic controls of SIVmac239 
infected animals had peak viral load measurements rang-
ing from 3.0 × 106 to 7.3 × 107 vRNA copies/ml. Three 
of the four SIVmac239Opt infected animals equilibrated 
to a steady state plasma viremia level of approximately 
106  copies/ml for over 150  days. The fourth macaque 
was a rapid progressor and was euthanized at day 87 fol-
lowing development of clinical signs of AIDS. In the his-
torical control group rapid progressors and controllers 
were not included. Excluding the single rapid progressor 
animal in the SIVmac239Opt infected cohort, we found 
no statistical difference between SIVmac239Opt and SIV-
mac239WT in peak viral load (p = 0.086) and set point 
(p = 0.768). Importantly, the variance in plasma viremia 
levels during the viral “set point” chronic phase of infec-
tion (from day 42–150 post infection) was significantly 
reduced in SIVmac239Opt-infected animals compared to 
SIVmac239 (p = 0.005 F test to compare variance). Fur-
ther, using a restricted maximum likelihood estimate of 
the standard deviation, we found that plasma viremia lev-
els for wild type SIVmac239 infected animals was more 
than twice as variable during this phase as the SIVma-
c239Opt infected animals (p = 0.0015 ANOVA).
SIVmac239OptX
We recently reported on a pool of molecularly tagged 
but otherwise isogenic variants of SIVmac239 wherein 
2–3 synonymous changes were introduced into the inte-
grase gene to generate genetically distinct but biologically 
equivalent versions of SIVmac239 [21]. These variants 
were designed to be combined into a “synthetic swarm” 
of sequence discriminable but biologically equivalent 
viruses that can be used to track independent infection 
events in viral transmission and dissemination; detailed 
analysis suggested that despite the introduction of only 
2–3 synonymous mutations, two of the variants showed 
decreased replicative capacity relative to the others (21). 
We transferred these same molecular tags from the wild 
type SIVmac239 into the optimized SIVmac239Opt clone 
and compared replication capacities of each tagged clone. 




















































Figure 2 Protein analysis of SIVmac239Opt. Coomassie blue stain (a) and Western immunoblots (b) prepared from SDS-page gels of purified SIV-
mac239WT (239WT) or optimized SIVmac239 (239Opt). Western blots were generated by probing for gp41, gp120, and capsid p27.
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only the reported mutations, each optimized clone was 
compared to the corresponding wild type clone for in 
vitro replication in SupT1-R5 cells (Figure 5). Similar to 
our in vitro replication curves in primary macaque cells, 
there were some cultures where the optimized virus sig-
nificantly out performed wild type (clones A, B, H, I, and 
untagged with p values <0.05 for each clone), but over-
all, optimized clones were not statistically different from 
wild type clones (p =  0.377 ANOVA). Interestingly, the 
reduced replicative capacity of variants D and I, which 
were reported previously [21] was recapitulated in the 
optimized versions, confirming our previous report that 
these two genotypes, despite only three synonymous 
mutations, restrict viral replication.
Primer binding site correction
In order to assess the relative fitness costs of each sub-
optimal nucleotide, wild type virus was grown in vitro 
on SupT1-R5 cells for 2  months and sampled at least 
weekly for sequence analysis of vRNA to identify mutants 
and selection of optimal nucleotides. By day 21, the PBS 
had completely changed to the optimal version but the 
Env and Pol mutations had not yet arisen. While the 
Env mutation occurred at approximately week 10, the 
Pol mutations were not seen within the 2 months of this 
experiment. Although it is clear from published research 
that all four are suboptimal clones that will mutate to 
optimal nucleotides given sufficient time and viral rep-
lication [1, 6], the mutation with the greatest impact on 
early replication appears to be the PBS mutation followed 
by the Env mutation. In fact, the PBS mutation accumu-
lated so rapidly that in order to precisely document this 
turnover we repeated the experiment sampling at 12 and 
24 h and then daily for 8 days. Single genome amplifica-
tion (SGA) was performed on cellular DNA to determine 
the proportion of sequences encoding the wild type, sub-
optimal thymine/adenine (T/A) pairing or the optimal 
cytosine/guanidine (C/G) dimer for the PBS mutation 
(Figure  6a). Sequence analysis from samples obtained 
within the first 24 h revealed that ~50% of all sequences 
contained the suboptimal dimer (T/A), and ~10% 










































Figure 3 In vitro replication curves of SIVmac239Opt and SIV-
mac239WT. In vitro replication dynamics of SIVmac239Opt were 
determined by measuring p27 capsid content six times over 14 days 
post-infection in CD4+ T-cell enriched PBMCs from three SIV-
naïve, Indian-origin rhesus macaques (a–c). Wild type SIVmac239 is 
displayed in a solid line, and the SIVmac239Opt is displayed with a 
dashed line.





















Figure 4 In vivo replication curves of SIVmac239Opt and wild type 
SIVmac239. Rhesus macaques were intrarectally infected with either 
SIVmac239Opt (green), or SIVmac239WT (pink). The average viral load 
of the macaques infected with SIVmac239WT is shown in red. One 
macaque infected with SIVmac239Opt rapidly progressed to AIDS 
and was euthanized at 87 days post infection.
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Figure 5 Replicative capacity of SIVmac239OptX. Replicative capacity of SIVmac239OptX was determined by measuring the p27 concentrations 
over 2 weeks of SupT1-CCR5 cultures infected with either individual variants of SIVmac239OptX or SIVmac239X. Optimized variants are plotted with 
dashed lines and the wild type variants are plotted with a solid line. a–i Depict comparisons for each pair of similarly tagged variants while j depicts 
the parental strains.
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contained the optimal pairing (C/G). The remaining 
~40% of all sequences contained a mismatched pairing 
of C/A at position 860 of the PBS. Since these sequences 
were obtained from DNA by SGA, where only a single, 
double stranded template is amplified for any given reac-
tion, we concluded that following reverse transcription 
and integration, the viral genome contains a mismatched 
pairing at the suboptimal PBS position. Careful examina-
tion of the complex reverse transcription process with a 
tRNA3Lys primer actually predicts a mixed base within the 
PBS (Figure  7). Interestingly, while the fraction of cells 













































Figure 6 Suboptimal correction and fixation of the mutation in the 
primer binding site (PBS) over time. SupT1-CCR5 cells were infected 
with SIVmac239WT (a) or with a nonreplicating SIVmac239WT∆Env 
which was pseudotyped with SIVmac239WT Env to produce a single 
round infection model (b). Samples were collected at 12 and 24 h 
and then daily. The PBS of the integrated genome was sequenced by 
SGA. For both panels, the percent of each variant per day is plotted 
and a linear trend line was added for each population. The percent-
age of sequences bearing the suboptimal thymine/adenine (T/A) 
base is shown in red, those bearing the optimal cytosine/guanine 
(C/G) base is shown in green, and those containing the mismatched 
cytosine/adenine (C/A) base is shown in blue.
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Figure 7 Model of tRNA-mediated mismatched integration of the 
PBS following viral reverse transcription. Proposed model of the 
method by which the mismatched pairing in the primer binding site 
is generated and integrated into the host genome. The tRNA3Lys binds 
the viral PBS and functions as a primer for the initiation of RT but 
retains a mismatched base to wild type SIVmac239 with a guanine to 
uracil (G/U) pairing. Reverse transcription progresses with the tRNA-
primed U5 region disassociating from the viral RNA PBS, and rean-
nealing to its 3′ end and continuing transcription through the PBS. 
Following complete RNAseH digestion of the parental RNA (except 
the PPT, which subsequently acts as a reverse primer for RT), the nas-
cent double stranded DNA circularizes and uses itself as template to 
complete transcription. Integration of the resulting double stranded 
viral DNA occurs with a mismatched base containing cytosine and 
adenine (C/A) at position 860 of the PBS. The base is generated from 
the primer is a C (green) and the suboptimal base is retained as an A 
(blue) on antisense strand which encodes a T in viral progeny. Length 
of viral genome not drawn to scale.
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with mixed bases was constant over the 8-day culture, 
we found that the proportion of the suboptimal pairing 
(T/A) decreased from ~50% of the sequences down to 
less than 10% and the proportion of the optimal nucleo-
tide bases (C/G) increased in the exact opposite amount 
from nearly 10% to over 50% (Figure 6a). The rate of loss 
of the suboptimal nucleotide and the reciprocal gain of 
the optimal nucleotide was ~5% per day.
For cells where the virus integrated as a mismatched 
pair, we reasoned that host repair mechanisms might edit 
this error by replacing either base, thereby converting the 
integrated viral genome into either the optimal or subop-
timal form and subsequent progeny virus would contain 
either the optimal or suboptimal nucleotide. Alterna-
tively, the mismatched base might not be corrected at all 
by the host in which case, progeny virus would be made 
containing the suboptimal nucleotide since the antisense 
strand following integration encodes for the suboptimal 
thymine. To elucidate the mechanism of PBS correc-
tion, we separated viral replication from host editing by 
infecting SupT1-R5 cells with a replication-incompetent 
(pseudotyped) SIVmac239. Following the single round 
infection, cell pellets were collected at 12 and 24  h and 
then daily for 8 days. Sequencing of host DNA was again 
performed with SGA to determine the proportion of 
sequences containing the suboptimal, optimal or mis-
matched bases (Figure  6b). As expected, the initial pro-
portion of the group was precisely as seen in our previous 
experiment prior to viral replication (Figure  6a). But 
by day 8 without viral replication, we saw a substantial 
decrease in the fraction of mismatched bases from ~40 
to ~10% of all sequences. Importantly, the suboptimal 
and the optimal nucleotides both increased at exactly the 
same rate (1.5% per day) over the first 8 days. Therefore, 
without viral replication, the host repair mechanisms 
correct the mismatched bases by forming either the sub-
optimal thymine/adenine (T/A) pairing or the optimal 
cytosine/guanine (C/G) pairing at the same rate.
There are two possible, but not mutually exclusive, 
mechanisms to explain the discrepancy in the proportion 
of suboptimal (50%) and optimal bases (10%) at the 12 h 
post infection time point found in both the infectious 
(Figure  6a) and the pseudotyped (Figure  6b) infection 
culture. This observation could be due to the presence 
of tRNA5Lys, a minor tRNA species initially detected in 
murine cells, which differs from tRNA3Lys in five nucleo-
tide positions, including a G to A mutation in the accep-
tor stem at position 69 [22]. This point mutation results 
in a tRNA isoacceptor stem that perfectly matches the 
suboptimal SIVmac239 PBS [3] allowing for the inte-
gration of a matched, but suboptimal T/A at site 860 in 
the PBS (Additional file 1: Figure S1A). Alternatively, 
a reduction in the processivity of RT that prematurely 
terminates the second strand synthesis prior to the mis-
match can then be replaced by the PBS from the first 
strand allowing for the incorporation of a thymine dur-
ing the final extension phase leading to a suboptimal T/A 
integrant (Additional file 1: Figure S1B). Furthermore, the 
10% optimal G/C either originates from rapid host repair 
or following incomplete first strand synthesis that fails to 
reach the 5′ PBS and utilizes only the optimal G in the 3′ 
PBS (Additional file 1: Figure S1C).
Regardless of the mechanism, the increased integration 
of the suboptimal T/A genome will produce virions with 
the suboptimal mutation in the PBS requiring additional 
rounds of replication to correct. Since progeny viruses 
arising from genomes retaining a mixed base will remain 
suboptimal, we propose a model for PBS correction with 
viral replication (Figure  8). For each replication cycle, 
progeny virus from both mismatched (C/A) and host 
repaired, but suboptimal (T/A) genomes will produce 
virus with a suboptimal PBS (uracil at site 860). Only host 
corrected, optimal (C/G) mutants will produce optimal 
progeny (cytosine at site 860) which provides the perfect 
nucleotide match for tRNA3Lys binding. Each subsequent 
round of replication will increase the proportion of opti-
mal mutants following host repair. During viral replica-
tion, the selection of these mutations increases due to 
their fitness advantage, but not the frequency in which 
they are generated. Additionally, given that unrepaired 
mismatched genomes produce suboptimal progeny, the 
rate of suboptimal correction is partially determined by 
the rapidity of host mismatch repair. Therefore, the speed 
by which the PBS mutant surpasses the suboptimal virus 
is determined by a combination the in vivo mismatch 
repair time of the host and the viral fitness advantage 
of having a matched PBS. The overall effect of the mis-
matched PBS/tRNA is an increase in animal to animal 
variation.
Discussion
Modeling HIV-1 transmission using non-human pri-
mates is an essential tool for elucidating the all stages of 
the disease. High-dose infection of macaques with SIV 
was, until recently, a commonly used model system as 
it essentially ensures infection upon challenge of naïve, 
untreated animals [23, 24]. Recent findings suggest that a 
limiting-dose challenge of SIV more accurately recapitu-
lates the transmission of HIV-1 in humans [17, 18, 25]. 
The experimental success of a limiting-dose challenge 
model is highly dependent upon a consistent infection 
with regular viral replication kinetics from one animal to 
another. Previous studies [1, 6] indicate that the most fre-
quently utilized strain of SIVmac239 harbors four subop-
timal nucleotide substitutions which may inhibit the viral 
replicative capacity until mutations spontaneously occur 
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Figure 8 Viral genotypes resulting from transcription of integrated, mismatched viral genome. Following integration as a mismatched base, the 
mutation in the PBS is corrected by the host proofreading mechanism to either a matched, suboptimal thymine/adenine (T/A); a matched, optimal 
cytosine/guanine (C/G); or remains uncorrected as a mixed base cytosine/adenine (C/A). The resulting progeny virus produced from each of these 
scenarios is depicted: the matched C/G will produce virus with an optimal (C) PBS, while the mixed base (C/A), and the suboptimal (T/A) will both 
produce virus with a suboptimal uracil (U) at position 860 within the PBS. Virions bearing the suboptimal U in the PBS will repeat the entire cycle 
and integrate as matched, optimal cytosine/guanine (C/G), matched suboptimal (T/A), or mismatched as seen previously. Virions with the corrected 
C in the primer binding site will subsequently only integrate as a matched C/G, and will only produce progeny virus with the corrected PBS.
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in the course of viral replication to revert these four bases 
to an optimal nucleotide, followed by increases in the 
population containing optimal nucleotides due to fitness 
advantages. Once fixed in the population, these muta-
tions appear to be permanent highlighting their new, 
optimal state. In this study, we used basic molecular biol-
ogy techniques to change the suboptimal bases in the 
primary SIVmac239 clone to the optimal nucleotides and 
subsequently characterized the modified virus in vitro 
and in vivo.
Our results indicated that the optimized virus showed 
in vitro infectivity comparable to the parental version 
with no obvious differences in protein production and 
processing. In vitro replicative capacity of SIVmac239Opt 
was also overall comparable to the levels observed in wild 
type SIVmac239. Although the optimized virus repli-
cated better in all primary CD4+ T cell cultures, and sig-
nificantly better in 1 of 3 cultures compared to the wild 
type virus, there were no significant differences overall. 
Replication in SupT1-CCR5 cells by the molecularly 
tagged version of SIVmac239OptX was used to compare 
replication of each of the ten tagged clones. We found 4 
of 10 clones exhibited significant increases in replication, 
but these were not significant when ANOVA analysis was 
performed using all ten clones. In vivo experiments with 
the optimized virus demonstrated plasma viral loads for 
SIVmac239Opt were comparable to historical measure-
ments for macaques infected with SIVmac239WT. Both 
peak viremia and set point viremia were not statistically 
different between the optimized virus and the wild type 
but similar to in vitro results, there were trends for higher 
levels in animals infected with SIVmac239Opt. Taken 
together, these data suggest that correcting the four sub-
optimal nucleotides likely increased replication capacity 
but with advantages not easily experimentally measured. 
Interestingly, the corrected nucleotides provided greater 
consistency during viral set point and chronic phase of 
infection in vivo likely due to the varying time required 
for changes to accumulate in different animals infected 
with the WT SIVmac239 containing the suboptimal 
nucleotides.
Our previous publication describes the benefits to 
inserting a silent molecular tag into the integrase gene 
of SIVmac239, allowing for enumeration of transmit-
ted/founder viruses while utilizing a clonal virus [21]. In 
order to study transmission more accurately by remov-
ing the uncontrolled variable of suboptimal nucleotide 
reversion, we added the silent molecular tags to SIVma-
c239Opt, leaving the rest of the genome unaltered. Each 
individual variant was tested for infectivity and replica-
tive competence in vitro. Each variant displayed simi-
lar kinetics to the wild type tagged virus SIVmac239X, 
and maybe a useful tool for studying the mechanism 
of transmission, dissemination, and acute replication 
dynamics.
Observing limited apparent replicative differences 
between the wild type and optimized versions of SIV-
mac239, we investigated how rapidly the four suboptimal 
nucleotides revert to their optimal base in wild type SIV-
mac239 infection in vitro. The primer binding site muta-
tion originated rapidly suggesting there was a significant 
selective advantage of perfectly matching the tRNA3Lys 
with the PBS. Integrated viral DNA was sequenced in 
SupT1-CCR5 cells infected with wild type SIVmac239 or 
a replication incompetent SIVmac239WT pseudotyped 
with wild type Env, with cell samples collected daily over 
the course of a week. We discovered that at early time 
points, the relative proportion of suboptimal, optimal, 
and mismatched bases at the PBS was identical in the 
sequences of the cells infected with a replication compe-
tent or pseudotyped virus. Over time in the replication 
competent culture, the proportion of optimal genomes 
increased at the same rate that the number of suboptimal 
genomes decreased (Figure  6a). In single round infec-
tion cultures, the proportion of optimal and suboptimal 
genomes increased at the same rate with the propor-
tion of mismatched genomes decreasing (Figure 6b). We 
conclude from these data that rather than the expected 
reversion through RT error, host repair mechanisms 
appear to be modifying the mismatched genome, cor-
recting it to either the suboptimal or the optimal version 
equally. When replication of the virus is allowed to pro-
ceed in the culture, we find an increase in the proportion 
of optimal genomes suggesting fitness advantage. We 
propose several models for explaining the mechanisms 
of these findings (Figure  8 and Additional file 1: Fig-
ure S1). In genomes bearing the suboptimal base in the 
PBS, the mismatch between the viral RNA and the host 
tRNA could potentially inhibit the efficiency with which 
the tRNA binds to the vRNA, a phenomenon which led 
to our initial hypothesis that the suboptimal SIVmac239 
would have decreased replicative capacity. While mis-
matched genomes (not yet corrected by the host) and 
suboptimal genomes both produce suboptimal viruses, 
optimized genomes produce only optimized viruses 
and once the optimized genome is acquired, there is no 
mechanism to return to the suboptimal form (Figure 8). 
Therefore, there is an cumulative effect of the optimized 
genome so that over several rounds of replication all 
genomes will eventually become optimized, which will 
occur with or without any selective advantage, because 
there is no mechanism for back mutations to the subopti-
mal form. Prior to this work, it was thought that this sub-
optimal mutation was so inefficient that selection for the 
optimal nucleotide occurred within weeks. However, this 
is not necessarily true and we have described a rare form 
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of viral mutation that explains both the rapid accumula-
tion of the PBS change and the limited fitness advantage 
we see in vitro and in vivo accompanying this change.
At the earliest time point following infection with repli-
cation competent or incompetent virus, the relative pro-
portion of suboptimal, optimal, and mismatched bases at 
the PBS was identical but different than expected. Our 
hypothesis that mismatches in the PBS would lead to mis-
matched integrated genomes predicted that all genomes 
would be mismatched and none would be resolved if 
sampled at the time of integration (Figure 7). We found 
that only 40% of the genomes were mismatched, while 
50% were still suboptimal and 10% were already optimal 
(Figure 6). It was unlikely that host correction occurred 
that rapidly since the rate of change in the replication 
incompetent cells was only 1.5% per day. There are two 
possible mechanisms to explain the fraction of each 
genome which are diagramed as models in Additional file 
1: Figure S1. The first model might explain the retention 
the suboptimal genome in half of the infected cells sam-
pled at 12 h post exposure. There is a minor tRNA spe-
cies (tRNA5Lys) originally detected in murine cells, which 
differs from tRNA3Lys in 5 nucleotide positions, includ-
ing a G to A mutation in the acceptor stem at position 
69 allowing for a perfect match with the suboptimal SIV-
maxc239 [22]. This novel tRNA was hypothesized to act 
as a primer in SIV and HIV variants, which bear the sub-
optimal thymine mutation in the primer-binding site. The 
minor presence of this tRNA could slow the reversion of 
the mutation in the PBS by mitigating the selective pres-
sure that would otherwise be caused by the absence of a 
perfectly complementary primer. The second model is an 
alternative, but not mutually exclusive, explanation for 
the retained 50% suboptimal genomes which includes 
a premature truncation of the second strand synthesis 
wherein the mismatched guanine is not incorporated into 
the 3′ end of the genome but the suboptimal thymine is 
incorporated with an adenine template from the 5′ PBS 
during the final extension prior to integration. These 
models could account for the higher than predicted pro-
portion of suboptimal genomes prior to replication or 
host repair. Furthermore, the reciprocal truncation could 
account for the 10% optimal genome seen just following 
integration. Here the first strand truncates at the 5′ PBS 
before reaching the mismatched (G/U). Again, correction 
occurs during the final extension of the first and second 
strand with the optimal cytosine of the second strand act-
ing as the correct template prior to integration. Although 
we have no direct evidence for these mechanisms, they 
have been suggested previously or are plausible since the 
mismatch template will be less stable and could be dis-
placed earlier than would occur with a perfectly matched 
primer.
While the overall difference between replication of the 
wild type and the optimized SIVmac239 was not signifi-
cant, both the in vitro and in vivo data suggest a mod-
est replicative advantage for SIVmac239Opt. Despite the 
limited extent of this apparent advantage, we found using 
two statistical measures that the SIVmac239Opt was over 
twice as consistent with regard to viral set-point chronic 
phase viremia levels compared to wild type SIVmac239. 
There are two limitations to this study that warrant dis-
cussion. Because this proof-of-concept study was an 
attempt to document the functionality of the optimized 
clone, the total number of SIVmac239Opt infections was 
limited to four animals. Furthermore, one of the four ani-
mals was a rapid progressor which might be related to the 
modest difference in replication of the optimized virus 
or might reflect non-viral host factors that predispose 
some animals to rapid progression. Additional infection 
studies should allow for the discrimination of these pos-
sible explanations. Overall, utilizing SIVmac239Opt and 
SIVmac239OptX might benefit NHP studies (especially 
preclinical vaccine evaluations and transmission studies) 
as it removes the uncontrollable variable of suboptimal 
nucleotide rates of reversion.
Conclusions
Our results demonstrate that SIVmac239Opt is a func-
tional alternative to parental SIVmac239, with marginally 
increased replication capacity. The addition of a silent, 
molecular tag provides a useful tool in discriminating 
different viral lineage and replication fitness of each SIV-
mac239Opt clone matched the parental clones. The PBS 
correction is due to host mechanisms that repair mis-
matched bases combined with the selective advantage of 
a perfectly complementary primed RT reaction. Utilizing 
the SIVmac239Opt and SIVmac239OptX might benefit 
NHP studies (especially preclinical vaccine evaluations, 
transmission studies, and pilot projects with limited ani-
mals) as this model eliminates the uncontrolled variable 
of suboptimal nucleotide reversion.
Methods
Site directed mutagenesis
Primers were designed to introduce the desired point 
mutations into the genome using site-directed mutagen-
esis utilizing Phusion high fidelity polymerase (Thermo 
Scientific). The GeneArt Seamless PLUS kit was then 
used to assemble the PCR fragments of the SIVmac239 
genome bearing the newly modified nucleotides (Life 
Technologies). The resulting plasmid was transformed 
into Max Efficiency Stbl2 cells (Life Technologies), 
expanded and purified by double banded cesium chlo-
ride centrifugation. Full-length genomic sequencing was 
performed on the final plasmid preps to confirm point 
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mutation generation and correct assembly of PCR frag-
ments. The resulting sequence-confirmed plasmid was 
designated SIVmac239Opt.
Virus preparation
Transfection-derived virus was prepared using Mirus 
Trans-IT 293 transfection reagent on Hek293T cells as 
described by manufacturer using the wild type or opti-
mized SIVmac239 molecular clones. Culture medium 
was changed 48  h post-transfection, and cell superna-
tants were collected at 72  h. Supernatants were passed 
through a 0.45  μm filter and stored at −80°C in 1  ml 
aliquots. Viral infectivity was determined using TZM-
bl reporter cells, which contain a Tat-inducible lucif-
erase and β-galactosidase gene expression cassette. 
Infectivity was determined by assessing the number of 
β-galactosidase expressing cells present after infection 
with serial dilutions of viral stocks. After dilution correc-
tion, wells containing blue cell counts falling within a lin-
ear range were averaged and used to determine the titer 
of infectious units (IU) per ml in the viral stock [26].
Protein analysis
To ensure that all proteins in the newly generated SIV-
mac239Opt were expressed and properly folded, pro-
tein characterization was performed. New viral preps 
were generated using the same SIVmac239Opt clones 
and transfection derived viruses prepared as described 
above with slight variation: the cellular medium was not 
changed and transfected supernatants were harvested 
at 48  h. The resulting 30  ml of supernatant was passed 
through a 0.45 μm filter, and concentrated down to form 
a viral pellet. Quantitative measurements of viral p27 
(CA) and gp120 protein in virions for determinations of 
gag:env ratios and estimations of Env trimer spikes per 
virion were determined using a dual-color fluorescent 
protein gel analysis. Gels with virus samples and a dilu-
tion series of purified protein standards were stained 
with two fluorescent dyes (Life Technologies), Pro-Q 
Emerald 300 (green fluorescence) to detect glycopro-
teins, such as Env (envelope glycoprotein complex), and 
SYPRO Ruby (red fluorescence) to detect all proteins, 
including p27 (CA). Stained gels were analyzed for fluo-
rescence at 520 nm with UV excitation by using a Chemi-
Doc MP imaging system (Bio-Rad Laboratories). The 
gp120 and p27 contents of each virion sample were cal-
culated by using the TotalLab densitometry software by 
interpolating the integrated pixel density signals from the 
unknown samples onto a standard curve derived from a 
linear regression of density values for serial dilutions of 
highly purified, quantitative amino acid analysis quanti-
fied standards, either recombinant vaccinia-produced 
HIV-1MN gp120SU (generously provided by B. Puffer and 
R. Doms, University of Pennsylvania, Philadelphia, PA, 
USA) or SIVmac239 cultured in human SupT1-CCR5 T 
lymphoblastoid cells virion-derived p27 (CA) and well-
characterized reference preparations of infection-derived 
HIVBAL, HIVNL4-3, and SIVmac239 (provided by J. Bess 
and the Biological Products Core, AIDS and Cancer 
Virus Program, Frederick National Laboratory, Frederick, 
MD, USA) were included in the analysis as controls.
In vitro replication
Replication curves were prepared by culturing CD8-
depleted Indian-origin rhesus macaque peripheral blood 
mononuclear cells (PBMCs) in RPMI supplemented 
with 10% fetal bovine serum (FBS), 2  mM  l-glutamine, 
and 100  U/ml penicillin and 100  μg/ml streptomycin 
(RPMI-complete), stimulated for 3  days with 5  μg/ml 
phytohemagglutinin (PHA) and IL-2 (100 U/ml). Stimu-
lated PBMCs and SupT1-CCR5 cells were infected with 
SIVmac239WT or SIVmac239Opt at an MOI of 0.01 or 
0.001 (as determined by TZM-bl). 24 h post inoculation, 
cell cultures were washed with phosphate buffered saline 
(PBS) twice and once with RPMI-complete to remove 
excess virus. Viral replication was monitored over 14 days 
by detection of the SIV p27 antigen in an enzyme-linked 
immunosorbent assay (ABL) according to the manufac-
turer’s provided protocol.
Animals and in vivo viral load monitoring
Four purpose-bred Indian-origin rhesus macaques 
(Macaca mulatta) were housed and cared for in accord-
ance with American Association for Accreditation of 
Laboratory Animal Care (AAALAC) guidelines in an 
AAALAC-accredited facility, and all animal proce-
dures were performed according to protocols approved 
by the Institutional Animal Care and Use Committee 
of the National Cancer Institute under the standards of 
the NIH Guide for the Care and Use of Laboratory Ani-
mals. All animals were free of cercopithecine herpesvi-
rus 1, D-type simian retrovirus, simian T-lymphotropic 
virus type 1, and simian immunodeficiency virus (SIV) 
at study initiation. Animals were genotyped for common 
MHC Class 1 alleles such as Mamu-A*01/-A*02/-B*08/-
B*17 using sequence-specific priming PCR performed as 
previously described [27]. Mamu-A*01, -B*08 and -B*17 
animals were excluded from this study. Intrarectal infec-
tions were performed by placing animals at ~20° down 
angle in an inverted Trendelenburg position (e.g. the 
animal’s pelvis was elevated above its head with its ster-
num against the table) and the atraumatic challenge was 
performed using 1  cc slip tip syringes (BD Biosciences) 
with a small amount of non-bacteriostatic, single-use, 
sterile lubricant. Using transfection-derived SIVma-
c239Opt, four macaques were challenged intrarectally 
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(i.r.) with 9 × 105 IU in a 3 ml volume. Blood draws were 
obtained every 2 weeks, and plasma viral loads assessed 
over 14  weeks by quantitative real-time PCR as previ-
ously described [28]. Historic control animals were from 
animals infected intrarectally with 100 or 300 IU of infec-
tion-derived virus. The animals included in this study are 
24760, 26795, 26993, 27036, 27127, 27519, 27522, 27525, 
27920 described in Del Prete et al. [21].
Molecularly tagging SIVmac239Opt
Our recent publication describes the addition of a molec-
ular tag of two or three synonymous changes to the inte-
grase gene of SIVmac239wt resulting in ten genetically 
distinct but phenotypically similar clones referred to as 
SIVmac239X [21]. These exact integrase molecular tags 
were inserted into the SIVmac239Opt clone using basic 
restriction digestion and ligation to generate nine tagged 
variants of SIVmac239Opt, designated SIVmac239OptA—
SIVmac239OptI. These clones were sequenced through 
the entire genome to ensure correct insertion of tags. Virus 
was prepared from all ten of the SIVmac239OptX (SIVma-
c239OptA—SIVmac239OptI plus SIVmac239Opt) clones 
using the Mirus Trans-It transfection protocol described 
above, and infectivity measured using the TZM-bl assay. 
In vitro replication curves were prepared as described 
above. The resulting cell-free supernatants were tested for 
viral antigen using the SIV p27 ELISA assay (ABL) using 
the manufactures’ protocol.
Defining the in vitro reversion of four suboptimal 
nucleotides
SupT1-CCR5 cells were infected with transfection-pro-
duced SIVmac239WT or a replication defective pseudo-
typed SIVmac239 with a luciferase reporter. Virus stocks 
were pre-treated with DNAseI for 1 h prior to infection 
to eliminate contaminating plasmid DNA. Cells were 
inoculated at a MOI of 0.01, and were spinoculated by 
centrifugation for 2 h at 1,000×g at 25°C, and then incu-
bated at 37°C with 5% CO2 for the duration of the experi-
ment. Infected cells were collected at 12, 24 h, and every 
subsequent day for 8  days. Collected cells were washed 
3× in PBS and DNA extracted using QIAamp DNA 
Mini kit (Qiagen). Temperatures during the extraction 
were maintained at room temperature or lower prevent 
DNA melting. SGA sequencing was performed by dilut-
ing template DNA such that the majority of wells contain 
no template and the wells with template most likely con-
tain only a single copy [21]. Briefly, PCR was performed 
with 1× PCR buffer, 2  mM MgCl2, 0.2  mM of each 
deoxynucleoside triphosphate, 0.2  μM of each primer, 
and 0.025  U/μl Platinum Taq polymerase (Life Tech-
nologies) in a 10-μl reaction. To sequence the molecu-
lar tag contained within integrase gene, real-time PCR 
was performed with sense primer SIVmacIntF1 5′-GAA 
GGG GAG GAA TAG GGG ATA TG-3′ and antisense 
primer SIVmacIntR3 5′-CAC CTC TCT AGC CTC TCC 
GGT ATC C-3′ under the following conditions: 1 cycle of 
94°C for 2 min, 40 cycles at 94°C for 15 s, 55°C for 30 s, 
60°C for 1.5  min, and 72°C for 30  s. Template positive 
reactions were determined using a gene specific probe 
SIVIntP 5′-TCC CTA CCT TTA AGA TGA CTG CTC 
CTT CCC CT-3′ with FAM6 and ZEN/Iowa Black Hole 
Quencher (Integrated DNA Technologies) and directly 
sequenced with SIVmacIntR3 using Sanger sequencing 
(Life Technologies). Additional SGA sequencing was per-
formed spanning each of the four suboptimal nucleotides 
to monitor reversion over time.
Statistical analysis
For comparisons of in vitro growth kinetics, paired t-tests 
were used with log10 transformed p27 measurements for 
each macaque. An ANOVA was then performed to iden-
tify difference between macaques. The same paired t-test 
and ANOVA was performed for each molecularly tagged 
variant in SupT1-R5 cells. The mean in vivo peak (day 12) 
and set point (days >42) viral loads between SIV239Opt 
and SIV239WT were compared using a two sample 
t-test and the variance around the mean was determined 
using a F test. Furthermore, the variance during set point 
was determined using a restricted maximum likelihood 
(REML) estimate in a random effects mixed model with 
an ANOVA analysis was then performed testing the dif-
ferences between the two mixed effects models.
Authors’ contributions
CMF participated in design of study, performed all in vitro assays, analyzed 
data, and wrote the paper. CR, LL, and LN performed and analyzed sequence 
data. KO and MP performed quantitative PCR. JDR and EC performed protein 
analysis. JS provided veterinary care and participated in the design of the 
study. WGA provided statistical analysis. GQDP, JDE, and JDL participated in 
the design of the study and helped draft the manuscript. BFK conceived the 
study, designed the experiments, analyzed the data, and wrote the paper. All 
authors read and approved the final manuscript.
Additional files
Additional file 1:  Figure S1. Possible models for the various propor-
tions of the suboptimal, optimal and mismatched integration within the 
PBS. Following initial integration, the proportion of suboptimal thymine/
adenine (T/A) integrated in the genome is 50% whereas the optimal cyto-
sine/guanine (C/G) is found at only 10% and the uncorrected mixed base 
of cytosine/adenine (C/A) is found at 40%. There are two possible models 
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